SLC5A2 and myocardial infarction: Compared with monotherapy, combination therapy with an SGLT2 inhibitor and a GLP-1 RA was associated with a lower risk of myocardial infarction (RR 0.62 [95% CI 0.48, 0.80], low certainty of evidence due to risk of bias and inconsistency; Fig. 2, Table 2) and stroke (RR 0.65 [95% CI 0.49, 0.86], low certainty of evidence due to risk of bias and inconsistency; Fig. 2, Table 2).